<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210802052054N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-14</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of vitamin D consumption on the AntiTPO</public_title>
      <acronym></acronym>
      <scientific_title>The effect of vitamin D intake on AntiTPO levels in hypothyroid and euthyroid patients with anti-TPO positive: an interventional study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>128</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57917</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.</study_design>
      <phase>2</phase>
      <hc_freetext>Autoimmune Hypothyroidism.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients who are Anti-TPO positive and have elevated TSH and are deficient in vitamin D whose serum level of vitamin D is less than 10ng /ml . For 8 weeks, 50,000 units of vitamin D3 tablets will be prescribed every week. After 8 weeks, 800 to 1000 units of vitamin D will be prescribed daily. Intervention 2: Intervention group: Patients who are anti-TPO positive and have elevated TSH and insufficient vitamin D with serum levels of vitamin D between 10ng/ml to 20ng/ml. 800 to 1000 units of vitamin D are prescribed daily for 3 months. Intervention 3: Intervention group: Patients who are anti-TPO positive and have normal TSH and are deficient in vitamin D whose serum level of vitamin D is less than 10ng/ml. For 8 weeks, 50,000 units of vitamin D3 tablets will be prescribed every week. After 8 weeks, 800 to 1000 units of vitamin D will be prescribed daily. Intervention 4: Intervention group: Patients who are anti-TPO positive and have normal TSH and insufficient vitamin D with serum levels of vitamin D between 10ng/ml to 20ng/ml. 800 to 1000 units of vitamin D are prescribed daily for 3 months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
A portion of the data will be shared.

When:
2023-2024

To whom:
Researchers and academic staffs

Conditions:
For further studies

Where to obtain:
Request via email:ali_you_2015@yahoo.co.uk

How to obtain:
Request via email :ali_you_2015@yahoo.co.uk

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sima Shahmohammadi Farid</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166/15731</zip>
        <telephone>+98 41 1334 3010</telephone>
        <email>shahmohammadis@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sima Shahmohammadi Farid</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166/15731</zip>
        <telephone>+98 41 1334 3010</telephone>
        <email>shahmohammadis@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients of both sexes who have AntiTPO positive and their disease is approved by an endocrinologist and are in the age range of 18 to 65 years.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who have evidence of any disease that affects the balance of the immune system, such as those with type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other autoimmune diseases.
Patients with impaired liver enzyme function
Malnourished patients
Patients with a BMI of less than 18 or more than 40.
Patients with hyperthyroidism and decreased TSH levels.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E06.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Autoimmune thyroiditis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients who are Anti-TPO positive and have elevated TSH and are deficient in vitamin D whose serum level of vitamin D is less than 10ng /ml . For 8 weeks, 50,000 units of vitamin D3 tablets will be prescribed every week. After 8 weeks, 800 to 1000 units of vitamin D will be prescribed daily.</i_keyword>
      <i_keyword>Intervention group: Patients who are anti-TPO positive and have elevated TSH and insufficient vitamin D with serum levels of vitamin D between 10ng/ml to 20ng/ml. 800 to 1000 units of vitamin D are prescribed daily for 3 months.</i_keyword>
      <i_keyword>Intervention group: Patients who are anti-TPO positive and have normal TSH and are deficient in vitamin D whose serum level of vitamin D is less than 10ng/ml. For 8 weeks, 50,000 units of vitamin D3 tablets will be prescribed every week. After 8 weeks, 800 to 1000 units of vitamin D will be prescribed daily.</i_keyword>
      <i_keyword>Intervention group: Patients who are anti-TPO positive and have normal TSH and insufficient vitamin D with serum levels of vitamin D between 10ng/ml to 20ng/ml. 800 to 1000 units of vitamin D are prescribed daily for 3 months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum levels of Anti TPO before and after taking vitamin D. Timepoint: Anti TPO levels are measured before the intervention and 3 and 6 months after the start of vitamin D intake. Method of measurement: After starting the study, blood samples are taken from the patients and the patients' serum is removed. Using special Anti TPO kits, the level of Anti TPO is measured by ELISA and the effect of vitamin D level on the level of Anti TPO in the serum is examined.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Evaluation of serum vitamin D levels in patients with Anti TPO positive. Timepoint: Serum vitamin D levels are measured before the intervention and 3 and 6 months after the start of vitamin D intake. Method of measurement: After starting the study, blood samples are taken from the patients and the patients' serum is removed. Using special Vitamin D kits, the level of vitamin D is measured by ELISA.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-13</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical sciences</contact_name>
        <contact_address>Central Office of Tabriz University of Medical Sciences Tabriz -Golghasht St.- Azadi St. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
